Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07029776 · ClinicalTrials.gov registry record · Phase 2
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
A Phase 2 study, sponsored by University of Arkansas.
- Not yet
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT07029776 is a Phase 2 study that has not yet begun recruiting, run by University of Arkansas. The registered enrollment target is 50 participants.
The verdict
NCT07029776, a Phase 2 study, has not yet begun recruiting, sponsored by University of Arkansas.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this research is to learn whether using teclistamab and talquetamab at different time points will improve survival in participants with high-risk Multiple Myeloma (MM). The treatment on this study will consist of Induction chemotherapy and stem cell collection, Immunotherapy 1 chemotherapy and Immunotherapy 2 chemotherapy. For participants whose testing show they are Minimal Residual Disease (MRD) positive (still have myeloma cells present in the bone marrow testing), a Melphalan-based stem cell transplant will be performed. For participants whose testing show they are MRD negative, the stem cell transplant will not be performed. All participants will go on to receive Immunotherapy 3 chemotherapy, Immunotherapy 4 chemotherapy, and Maintenance therapy.
Interventions
- DRUG teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance
- PROCEDURE melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2032-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07029776
The ClinicalTrials.gov registry entry for NCT07029776 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance is the first listed.
NCT07029776 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07029776 about?
NCT07029776 is a clinical study titled "MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma". The purpose of this research is to learn whether using teclistamab and talquetamab at different time points will improve survival in participants with high-risk Multiple Myeloma (MM). The treatment on this study will consist of Induction chemotherapy and stem cell collection, Immunotherapy 1 chemot...
What is the current status of trial NCT07029776?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2026-07-01. Estimated completion is 2032-04-01.
What interventions are being tested in trial NCT07029776?
The interventions under investigation include: teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance (DRUG), melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy (PROCEDURE).
Who is sponsoring clinical trial NCT07029776?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.